Main menu

SeqOne Genomics and the French CNR-MAT pioneer the use of Oxford Nanopore sequencing technology to improve outcomes in kidney disease while reducing turnaround times


SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies(CNR-MAT), aimed at improving outcomes in thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS), using Oxford Nanopore sequencing technology.

You can read the full announcement from SeqOne here.

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag